Safety of the AS04-adjuvanted human papillomavirus (HPV)-16/18 vaccine in adolescents aged 12–15 years: end-of-study results from a community-randomized study up to 6.5 years

This manuscript discloses end-of-study safety data of a community-randomized controlled trial in Finland (NCT00534638), assessing the effectiveness of two vaccination strategies (gender-neutral versus females only) using the AS04-adjuvanted human papillomavirus (HPV)-16/18 (AS04-HPV-16/18) vaccine....

Descripción completa

Detalles Bibliográficos
Autores principales: Bi, Dan, Apter, Dan, Eriksson, Tiina, Hokkanen, Mari, Zima, Julia, Damaso, Silvia, Soila, Maaria, Dubin, Gary, Lehtinen, Matti, Struyf, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7482795/
https://www.ncbi.nlm.nih.gov/pubmed/31829767
http://dx.doi.org/10.1080/21645515.2019.1692557

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7482795/
https://www.ncbi.nlm.nih.gov/pubmed/31829767
http://dx.doi.org/10.1080/21645515.2019.1692557

Ejemplares similares